STOCK TITAN

Tarsus Pharmaceuticals Inc - TARS STOCK NEWS

Welcome to our dedicated news page for Tarsus Pharmaceuticals (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tarsus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tarsus Pharmaceuticals's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.81%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
conferences
Tarsus Pharmaceuticals Inc

Nasdaq:TARS

TARS Rankings

TARS Stock Data

1.36B
24.39M
4.26%
90.03%
20.93%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Irvine

About TARS

tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.